Biostatistics in IVD Clinical Research – What Can Make or Break your Product’s Commercialization

Release Date
July 30, 2019 10 AM ET U.S.

Register here!

As an integral part of IVD clinical research, a sound biostatistical strategy is essential to achieving commercialization. Regardless of the intended market, end user or purpose of your product, there is one design element that needs to be the center of your strategy. Learn how to understand your assay’s precision profile and how to apply it to your clinical research, data management and biostatistical reports to facilitate market approval. 

Topics to be covered during this webinar include:

Time will also be allotted for Q&A.

Register here!

About the Presenter:

 

Ben Brown

Senior Biostatistician, NAMSA

Ben has been in the industry for 7 years and has found his niche specifically in IVD and companion diagnostics related projects. Ben is known for his collaborative strength of incorporating biostatistical strategy into clinical research setup, execution and data management that results in precise reporting to support market approval.

Ben has been serving multiple clients with NAMSA IVD since 2017 after completing his Ph.D. from the University of Minnesota, where he was a clinical trial research assistant for an HIV treatment. His dissertation focused on developing machine learning methods to perform signal detection in high dimensional data with correlated outcomes and variables measured with error. Before his Ph.D. program, Ben gained an industry view on biostatistics during his stint at 3M and holds a B.A. in mathematics with a concentration in statistics from St. Olaf College, where he now serves as an Adjunct Assistant Professor of Statistics.

In addition to his B.A. and Ph.D., Ben has completed several industry trainings including Good Clinical Practices, SAS Macro Language 1, SAS Programming Essentials 1 and SAS Programming Essentials 2. His personal affiliations include the American Statistical Association and the International Biometrics Society.